Get the app
US › Healthcare

Keros Therapeutics Inc (KROS)

US · Healthcare · Biotechnology

$11.36+5.77%
Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue
$18.2M
Revenue YoY
0.0%
Net profit
$-28.7M
EPS
$-1.45
EPS estimate
$-1.25
Net margin
-158.0%

EPS came in at -1.45 against a street estimate of -1.25 — a miss of 16.0%.

Key statistics

Market cap
$219.7M
Forward P/E
48.8
P/B
0.84
Book value
$13.23
EPS (TTM)
$-3.22
52-week high
$22.55
52-week low
$9.69
50-day MA
$10.83
200-day MA
$13.53
Beta
1.02

Analyst view

Analysts rate Keros Therapeutics Inc a buy (7 buy, 6 hold, 0 sell out of 13) with an average price target of $19.83.

Shareholding

Insiders
3.96%
Institutions
95.20%

Largest institutional holders

FundStake
BlackRock Inc12.16%
Nantahala Capital Management, LLC6.86%
Vanguard Capital Management, LLC4.19%
Orbimed Advisors LLC3.83%
Qube Research & Technologies3.66%
Jacobs Levy Equity Management, Inc.3.56%
Federated Hermes Inc3.53%
Vanguard Portfolio Management, LLC3.44%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Keros Therapeutics Inc — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncMerck & Company IncUnitedHealth Group IncorporatedNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncAmgen IncNovo Nordisk A/SGilead Sciences IncAbbott Laboratories

Data updated 2026-09-18.